Three Key Points to Prepare for an Early Phase Clinical Trial
Companies preparing for an early phase study must deal with an array of challenges and decisions for biometrics, pharmacovigilance and regulatory...
We see a continued need from our clients, both large and small, to partner with organizations that can deliver meaningful and actionable solutions focusing on usability, design, and engineering in phase 0 through phase 2 front-end engagements. That’s why we offer a quick-turn proof-of-concept solution.
The structure is a light, adaptable, but targeted approach. The awareness and ability to adapt to our clients’ needs and processes is critical. We’re deliberate in assembling small, bespoke teams of designers and engineers with proven track records to rapidly synthesize data and convert those needs into actionable and impactful solutions – often against wildly aggressive timelines. These timelines can be as little as four weeks. For our clients, this is a relatively small investment in time and capital that dramatically reduces risk and positions them safely on a product development pathway.
Every client is different. Their needs, timelines, budgets, and processes are always unique. Regardless of their scale and resources, large capital or startup, being able to explore, embody, and vet conceptual solutions quickly and with confidence can be one of the biggest determining factors of whether a product or approach will be successful. “Fail fast” is a common saying, but “succeed fast,” is the goal.
At a high level, going this route de-risks a concept to a point of confidence before the client needs to fully commit resources to a development effort. This process allows clients to:
We have a strong core team with an established and profound internal expertise and passion to execute against the market need of fast to proof-of-concept. Our design engineers and industrial designers have the experience to execute rapidly and with minimal resources to a high degree of success and are well-connected and respected resources within the medtech industry. Plus, our track record speaks for itself – last year, this group had a 90%+ continuation or multiple continuation rate.
Companies preparing for an early phase study must deal with an array of challenges and decisions for biometrics, pharmacovigilance and regulatory...
First-in-Human studies are a discovery point, which can decide the fate of a compound as well as lay the groundwork for subsequent phases of a...
2 min read
Is specialized knowledge needed for Medical Writers working on early phase studies? Based on the characteristics and needs of Phase 1, 1a, 1b, BA-BE...